Toshiba’s Contrast-Enhanced Ultrasound Offers Safer Exams and Helps Improve Diagnostic Confidence

TUSTIN, Calif., Sept. 7, 2016 – To show the benefits of the recent FDA approval of ultrasound contrast for characterizing liver lesions in adults and pediatrics, Toshiba America Medical Systems, Inc.’s AplioTM 500 Platinum ultrasound system, with its comprehensive contrast imaging package, will be used during a live case following the International Contrast Ultrasound Society (ICUS) Bubbles Conference, September 8–9, 2016, in Chicago.

The live case will be performed on Saturday, September 10, 2016, at Rush University Medical Center, Tower Procedure Lab in Chicago, between 9:30 a.m. and 1:30 p.m. CT.

“Toshiba’s Aplio 500 Platinum ultrasound offers a comprehensive and integrated technology package that allows clinicians to make diagnoses with confidence,” said Dr. Stephanie Wilson, co-president, International Contrast Ultrasound Society. “The system offers excellent resolution and image quality with a complete suite of tools to perform contrast-enhanced ultrasound, spectral and color Doppler or elastography. This allows clinicians to evaluate the entire patient.”

“Contrast-enhanced ultrasound provides clinicians with clearer images so they can diagnose accurately, which reduces the need for additional and expensive exams like CT or MRIs,” said Dr. Steven Feinstein, co-president, International Contrast Ultrasound Society. “There are long wait times to get a CT or MRI exam, and contrast-enhanced ultrasound imaging helps patients get a diagnosis faster, often within 24 hours.”

Toshiba’s Aplio 500 Platinum ultrasound system provides powerful clinical imaging technology for advanced visualization, quantification and intervention. Both Toshiba’s Aplio 500 Platinum and Aplio 300 Platinum offer a comprehensive contrast imaging package that allows clinicians to assess perfusion dynamics in a wide range of clinical settings.

“The FDA approval of contrast-enhanced ultrasound for liver lesions in both adults and pediatrics is an important step in improving the clinical utility of ultrasound, offering less expensive, safer and faster exams with no radiation,” said Satrajit Misra, vice president, Marketing and Strategic Development, Toshiba. “We designed Toshiba ultrasound systems to give healthcare providers the right tools to assist in the diagnosis of patients as quickly as possible, and our contrast imaging package expands their diagnostic tool box.”

About Toshiba America Medical Systems, Inc.

With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and cardiovascular equipment, and coordinates clinical diagnostic imaging research for all modalities in the United States. For more information, visit Toshiba’s website atwww.medical.toshiba.com.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.